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Abstract
Background: Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant condition characterized by dermatologic
lesions, pulmonary manifestations, and renal tumors. The syndrome arises from germline mutations in the folliculin
(FLCN) gene. We present findings from the single largest family BHD cohort described to date. Primary objectives
were to characterize cystic lung changes on computed tomography (CT) chest scanning and identify features that
stratify patients at higher risk of pneumothorax. Secondary objectives entailed description of the following: type
and natural history of BHD-associated pneumothorax, pulmonary function characteristics, and relationship between
cystic lung changes and pulmonary function.
Methods: The study was a retrospective chart review for a case series of a single family. Over 70 family members of
a proband with documented BHD were identified, 68 of which consented to genetic testing. All those with
confirmed BHD were offered a clinical assessment by the Medical Genetics and Pulmonary services which included
a history, physical exam, complete pulmonary function tests, and computed tomography (CT) scan of the chest and
abdomen.
Results: Thirty-six individuals had a heterozygous mutation in the FLCN gene (c.59delT). Of these, 100 % (28/28) had
pulmonary cysts, 41 % (13/32) had spontaneous pneumothoraces, 26 % (8/31) had kidney cysts, 3 % (1/31) had
renal tumors, and 53 % (18/34) had dermatologic manifestations. Recurrent pneumothoraces were common (40 %).
Cyst size (OR 3.23, 95 % CI 1.35–7.73) and extent of lower lung zone disease (OR 6.43, 95 % CI 1.41–29.2) were the
only findings associated with pneumothorax. The size or extent of cystic disease did not correlate with lung
function results.
Conclusions: This is the largest single family cohort of patients with BHD syndrome documented to date. We
found that all individuals had pulmonary cysts, pneumothoraces were common, and cyst size and lower lobe
predominant disease were associated with pneumothorax. Lung function was generally preserved and not affected
by a high cyst burden.
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Background
Birt-Hogg- Dubé (BHD) syndrome is a rare autosomal
dominant condition characterized by skin lesions, pul-
monary cysts, spontaneous pneumothoraces, and renal
tumors [1].
It was first described as an inherited dermatologic syn-
drome in the 1970s, however future studies identified
pulmonary and renal manifestations as key features of
the disease [2]. The gene responsible for the syndrome,
FLCN, was mapped to chromosome 17p12q11.2 [3] and
cloned in 2002 [4]. The product, folliculin, is found in
many normal tissues and thought to play a role in tumor
suppression [4]. There are over 70 unique pathogenic
FLCN gene mutations [5].
BHD dermatologic lesions are common and include
fibrofolliculomas (face, trunk, and arm papules), trichodis-
comas, and acrochordons (skin tags) [6]. Renal cysts and
tumors (including chromophobe renal cell carcinoma) are
frequently seen and are often multiple and bilateral [7].
Lung cysts are also common and the age-adjusted risk of
pneumothorax has been estimated as high as 50.3 [8, 9].
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Only 430 families worldwide have been documented
with BHD Syndrome [10, 11], with the largest reporting
twenty-five affected members [12]. We present findings
from the largest single family cohort described to date.
The primary objective of the case series was to
characterize the cystic lung changes on computed tom-
ography (CT) chest scanning and identify features that
stratify patients at higher risk of pneumothorax. The
secondary objectives included: (1) description of the
type and natural history of BHD-associated pneumo-
thorax; (2) pulmonary function characteristics; and (3)




The study was a retrospective chart review for a case
series of a single family. Genetic testing, pulmonary
function tests, and imaging were performed as part of
the patients’ routine clinical assessment. Our study did
not proceed to formal ethics review given the retrospect-
ive and case series nature of the project.
Population
The proband was diagnosed with BHD in the context of
several unprovoked pneumothoraces and a strong family
history of spontaneous pneumothoraces. A heterozygous
mutation in the FLCN gene (c.59delT), resulting in pre-
mature protein truncation, was identified in this individ-
ual. Following the diagnosis of BHD syndrome, cascade
genetic testing was offered to family members with pos-
sible clinical features of BHD and on a predictive basis
for asymptomatic at-risk individuals,with 68 people
agreeing to formal genetic testing. Inclusion criteria for
the case series included: (1) age 18 and greater (2) direct
relation to the proband (not through marriage) and (3)
documentation of the FLCN gene mutation.
A family history was compiled using information pro-
vided by the proband and multiple relatives. The pedi-
gree included over 150 individuals from six generations
originating from a matriarch and patriarch born in the
late nineteenth century (Fig. 1). The proband was one of
13 siblings.
Genetic assessment and confirmation of BHD syndrome
Genetic testing was performed using the same standardized
assay and equipment in the Alberta Children’s Hospital
Molecular Diagnostics Laboratory. Initial sequencing on
the proband was performed following Polymerase Chain
Reaction (PCR) amplification using primers flanking each
exon allowing for analysis of exonic plus flanking intronic
sequence. Subtraction analysis using Mutation Surveyor
(SoftGenetics) software was used to identify differences
between the patient and a reference sequence. The
Molecular Diagnostic Lab then performed targeted se-
quence analysis to detect this mutation in consenting
family members. Genomic DNA isolated from whole
blood was PCR amplified for exon 4 of the FLCN gene
and sequenced using the Sanger method to identify the
presence of the FLCN c.59delT mutation.
Clinical assessment
All individuals with the FLCN mutation were offered a
clinical assessment by a respirologist including history,
physical exam, CT scan of the chest, CT or magnetic
resonance imaging (MRI) scan of the abdomen, and
complete pulmonary function tests. Lung function test-
ing, including spirometry and diffusing capacity for car-
bon monoxide (DLCO), was performed in accordance
with ATS standards and using the well-validated Knudson
1983 normset [13–15]. Lung function tests performed at
the time of the individual’s BHD diagnosis were used for
data analysis. Clinical data was not collected from family
members who did not have the gene mutation or undergo
genetic testing.
Chest imaging
Non-contrast, chest CT with 5 mm slices were per-
formed. Images were reviewed by a thoracic radiologist
who was blinded to the clinical history. CT scans were
scored according to the following criteria: (1) cyst size
(based on greatest diameter on axial sections), (2) cyst
number (1, 2 to 5, or numerous), (3) extent of upper
Fig. 1 Pedigree of BHD affected family. The proband is indicated by the arrow on the far left. BHD affected individuals are highlighted in black
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lung zone involvement (0–5 %, 5–25 %, 25–50 %, 50–
75 %, or greater than 75 % of area affected by cysts), (4)
extent of lower lung zone involvement (0–5 %, 5–25 %,
25–50 %, 50–75 %, or greater than 75 % of area affected
by cysts), and (5) cyst distribution (upper lung zone pre-
dominant, lower lung zone predominant, right side pre-
dominant, left side predominant, or equal through-out).
The lungs were divided into upper and lower zones at
the level of the right main pulmonary artery. There is no
existing rating system for cystic lung disease. Therefore,
the divisions for extent of upper and lower lung involve-
ment as well as cyst number were arbitrary and made a
priori.
Statistical analysis
Descriptive analysis was applied to the patient charac-
teristics. Simple logistic regression was performed to
identify variables associated with pneumothorax. A full
model was constructed from variables identified as
associated with pneumothorax on univariate analysis
(p <0.05). Backwards selection was performed by
successively dropping the least significant variables until
all remaining variables were statistically significant
(Stata STAT/IC 13 software).
Results
Cohort demographic and clinical characteristics
Over seventy individuals from a single family were iden-
tified as biologic relatives of the proband and 68 of these
consented to genetic testing. Of those tested, 36 were
positive for the FLCN c.59delT. Twenty-eight individuals
had CT scans of the chest and abdomen and 22 of these
had a complete clinical assessment (Fig. 2).
Baseline characteristics of the study population are
summarized in Table 1. There were similar numbers of
men and women. The average age at diagnosis was
42 years (range of 19–71 years). More than 50 % of sub-
jects had an unknown smoking status or were current or
former smokers. Seventeen percent of the group had
asthma (as defined in Table 1). Thirty-six percent (8/22)
had airflow obstruction; 6 were secondary to asthma and
2 due to unknown etiology. Of those who had diffusing
capacity for carbon monoxide (DLCO) testing, the ma-
jority (11/19 or 58 %) were within normal limits. Seven
subjects (37 %) had an elevated DLCO.
Manifestations of BHD syndrome
Clinical sequelae of BHD syndrome are summarized in
Table 2. All patients who underwent CT chest imaging
had pulmonary cysts. The mean cyst size was 2.9 cm
Fig. 2 Patient Flow Chart. ^Chest imaging entailed a CT scan. *Abdominal imaging imaging was performed with MRI in 3 individuals (due to
radiation or contrast concerns with CT). ** Referral to Medical Genetics refers to a formal appointment to review patient clinical history (genetic
testing may have been performed in individuals due to family history with their consent in the absence of formal appointment Medical Genetics
appointment with functional inquiry)
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(SD 0.37) ranging from 0.7 to 9 cm in maximal diameter.
The majority (83 %) had lower lung zone predominant
cysts. There was no association between smoking and
cyst size or number. Thirteen subjects (41 %) had at
least one spontaneous pneumothorax. The mean age at
first pneumothorax was 35.6 (SD 2.37) years. Seven
subjects had multiple pneumothoraces; one individual
had bilateral involvement at presentation. Among the
remaining 6 people who experienced recurrent episodes,
half of them had 4 pneumothoraces each. Of the 25 total
pneumothoraces, there were a similar number of right
and left sided occurrences (13 and 11, respectively; the
location of one was unknown). Ten of the pneu-
mothoraces were recurrent, 6 of which were on the
contralateral side.
Of the total pneumothorax episodes, 21 (84 %) under-
went an interventional procedure; chest tube insertion in 9
cases and thoracic surgery (as primary treatment) in 12.
Of those undergoing surgical intervention, 8 were treated
with bullectomy/pleurectomy, 2 underwent combination
pleurectomy and wedge resection, 1 was managed with
lobectomy alone, and in 1 case the surgical details were
unclear. The number of pleurodesis procedures or the type
(chemical or physical) could not be ascertained from the
available data. The recurrence rate for pneumothoraces
managed by chest tube alone was 16 % (1/6) and for those
managed by surgical intervention was 9 % (1/11).
Dermatologic manifestations (primarily fibrofolliculo-
mas) occurred in 53 % of the cohort. Twenty-six percent
had kidney cysts and one individual was diagnosed with
an unclassified renal cell carcinoma on routine screen-
ing, which was successfully removed. One individual had
a pituitary tumor, a variant of spindle cell oncocytoma.
No direct correlation between BHD syndrome and pitu-
itary tumors has been documented [6].
There were no clinical features or measures of pul-
monary function associated with higher likelihood of
pneumothorax (Table 3). In contrast, both cyst size (OR
3.23, 95 % CI 1.35–7.73) and extent of lower lung zone
disease (OR 6.43, 95 % CI 1.41–29.2) were associated
with pneumothorax. Specifically, those with pulmonary
cysts with a maximum diameter less than 2.9 cm had a
significantly lower risk of spontaneous pneumothorax
(OR 0.06, 95 % CI 0.01–0.40). Individuals with more
than 25 % lower lung zone cyst involvement were 5
times more likely to experience pneumothorax (OR 4.57,
95 % CI 0.88–23.7). Other imaging features, including
cyst number, cyst distribution, and extent of upper lung
zone disease were not associated with a higher likelihood
of pneumothorax (Table 3).
Discussion
This is the largest single family BHD cohort reported in
the literature to date. There are approximately 430 fam-
ilies with BHD syndrome documented in the literature.
We found that all individuals had pulmonary cysts,
pneumothoraces were common, and cyst size and lower
lobe predominant disease were associated with pneumo-
thorax. Lung function was generally preserved and not
affected by a high cyst burden.
Table 1 Baseline characteristics
Characteristic Value
Age at Diagnosis, yrs 42 (3.1)
Male:Female 18:18





Unknown status 12 (33)
Smoking, pack years 6.9 (3.05)
FEV1, L 3.32 (0.21)
FEV1 (% pred) 92 (3.64)
FVC, L 4.40 (0.27)
FVC (% pred) 101 (4.10)
FEV1/FVC 74.8 (2.07)
DLCO, mL/min/mmHg 33.32 (2.26)
DLCO (% pred) 130 (6.72)
DLCO/VA, mL/min/mmHg 27.1 (3.66)
DLCO/VA (% pred) 130 (5.67)
DLCO, mL/min/mmHg (Asthmatics excluded) 33.0 (2.56)
DLCO (% pred) (Asthmatics excluded) 133.9 (7.40)
Asthma diagnosis, n (%) 6 (17)
Asthma was defined as full reversibility of airflow obstruction following
bronchodilator administration or a positive methacholine challenge test. Data
are shown as mean (SD)
Abbreviations: BMI body mass index, DLCO diffusing capacity for carbon
monoxide, FEV1 forced expiratory volume in one second, FRC functional
residual capacity, FVC forced vital capacity
Table 2 Clinical features of bhd cohort
Finding Prevalence (%)
Pulmonary







Cystic Lesions 8/31 (26)
Malignant Lesions 1/31 (3)
Other Malignancy 1/31 (3)
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Previous studies included multiple families and were
characterized by several genotypes [1, 8, 9, 12, 16–24].
In contrast, our cohort consisted of a single Caucasian
family with a FLCN c.59delT mutation; thus providing a
more homogenous phenotype.
In our cohort, every individual had pulmonary cysts
on CT chest imaging. The high penetrance of lung cysts
was in keeping with existing BHD literature (83 to 100 %)
[9, 12, 16–21, 23, 24]. The prevalence of pneumothorax
was slightly higher than that observed in the four largest
BHD studies, which ranged from 24 to 32 % [1, 8, 9, 12].
However, pneumothorax prevalence as low as 8 % [22, 24]
and as high as 93 % [20] has been described. Cyst size and
extent of lower lung zone disease were found to be associ-
ated with pneumothorax. This is supported by previous
literature, although cyst volume, number, and right middle
location have also been reported to be associated with
pneumothorax risk [9]. In contrast to Zbar and colleagues’
finding [8], age was not associated with pneumothorax.
Our recurrent pneumothorax rate was 42 %, which
falls between the previously reported rates of 25 and
75 % [8, 9]. Most of the documented pneumothoraces
required management with an interventional procedure,
similar to prior studies [9]. The recurrence rates were
substantially reduced post treatment, especially post sur-
gery. Furthermore, it has been suggested that chemical
pleurodesis or pleural ablation (which can be used to
prevent recurrence of primary and secondary pneu-
mothoraces) would be of even greater benefit in BHD
given the often diffuse nature of the lung disease [25].
Others have extrapolated from lymphangioleiomyomato-
sis (LAM) data that chemical pleurodesis and surgical
intervention have comparable outcomes in preventing
pneumothorax recurrence [26].
The optimal method and timing of treating BHD-
associated pneumothorax is unclear and controversies exist
as randomized prospective trials are lacking. Some reviews
suggest that BHD-associated pneumothorax should be
managed the same as in the general population [27]; others
argue that with the lower likelihood of spontaneous reso-
lution and the high likelihood of recurrence, pneu-
mothoraces should be managed more aggressively in this
population [26]. Given the available data [9] in combination
with our findings we would suggest the latter; clinicians
should have a lower threshold to treat BHD-associated
pneumothorax with tube thoracostomy (where indicated)
as well as consider early referral for a surgical opinion.
Our study had the largest collection of BHD subjects
to date who underwent lung function testing. Interest-
ingly, we found the majority had preserved DLCO, with
a subset having supranormal values. This was not ex-
plained by test technique, equipment problems, body
surface area, or asthma exacerbation. Although the rea-
son for these outliers is unclear, this finding could pos-
sibly be explained by factors that were not systematically
assessed (such as polycythemia, early heart failure, pul-
monary hemorrhage, pretest exercise, or the occurrence
of a Mueller maneuver during testing). In contrast, prior
studies documented a low normal or mildly reduced
DLCO in the context of BHD [17, 18, 28]. Lung volumes
were preserved in our cohort, consistent with existing
literature [17, 18, 28]. Our study suggests that individ-
uals with BHD may have even milder impairments in
lung function that previously thought [17, 18]. A novel
finding was the observation that burden of cystic lung
disease did not affect lung function.
Table 3 Pneumothorax risk factors
Baseline characteristics OR SD P 95 % CI
Sex 0.40 0.30 0.23 0.09–1.76
Age 0.97 0.03 0.43 0.92–1.03
BMI 1.03 0.11 0.79 0.83–1.28
Height 0.97 0.05 0.67 0.88–1.07
Smoker 1.00 - - -
Smoking Pack years 1.18 0.14 0.15 0.94–1.47
Asthma 0.35 0.35 0.29 0.05–2.47
FEV1/FVC absolute 0.92 0.05 0.16 0.83–1.03
FEV1 % predicted 0.98 0.026 0.52 0.93–1.03
FVC % predicted 1.00 0.02 0.88 0.96–1.05
DLCO % predicted 0.98 0.017 0.24 0.95–1.01
Renal Cysts 1.33 1.23 0.75 0.22–8.22
Dermatologic findings 1.30 0.94 0.72 0.32–5.33
Cyst Number
Few (<5 cysts) 0.51 0.47 0.47 0.08–3.14
Numerous (>5) 1.96 1.82 0.47 0.32–12.1
Cyst Size 3.23 1.44 0.008 1.35–7.73
0–2.9 cm diameter 0.06 0.06 0.003 0.01–0.40
3–10 cm diameter 15.4 14.3 0.003 2.49–95.1
Cyst Distribution 0.62 0.22 0.18 0.30–1.25
Extent of Upper Lung 1.75 1.12 0.38 0.50–6.15
Zone Disease
(% volume affected by cysts)
< 25 % of UL 2.25 2.74 0.51 0.21–24.4
> 25 % of UL 0.44 0.54 0.51 0.04–4.82
Extent of Lower Lung 6.43 4.96 0.016 1.41–29.2
Zone Disease
(% volume affected by cysts)
< 25 % of LL 0.25 0.22 0.12 0.04–1.45
> 25 % of LL 4.57 3.89 0.07 0.88–23.7
Asthma was defined as full reversibility of airflow obstruction following
bronchodilator administration or a positive methacholine challenge test
Abbreviations: BMI body mass index, DLCO diffusing capacity for carbon
monoxide, FEV1 forced expiratory volume in one second, FVC forced vital
capacity, UL upper lobe, LL lower lobe
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With respect to extrapulmonary manifestations, der-
matological findings were noted in only 53 % of the co-
hort, which was lower than the 79–100 % prevalence of
skin involvement documented in most BHD cohorts [1,
9, 12, 24]. This could be related to the relatively young
average age at diagnosis in this cohort, as BHD related
skin findings are more common starting in the third to
fourth decade of life [27]. Renal cysts were found in
26 % of those with imaging, which was higher than the
15 % observed in the only other study that specifically
quantified renal cysts [24]. In contrast, the 3 % preva-
lence of renal tumors documented in our cohort was
significantly lower than the 12–27 % seen in the four lar-
gest BHD studies [1, 8, 9, 12]. This may be explained by
sample size as some smaller cohorts also quoted 5 to
6 % prevalence of renal cancer [20, 22].
There are a few limitations to this study. First, this is a
retrospective review. However, the clinical assessments
were very detailed with pulmonary function testing and
imaging performed in most subjects. Second, the sample
size is smaller than previously reported pooled cohorts.
However, this is the largest single-family cohort de-
scribed in the literature with the same genotype, allow-
ing analysis of a uniquely homogenous population.
Furthermore, our study highlights the concept that un-
derstanding the clinical phenotype of an individual with
BHD might predict the phenotype of other affected fam-
ily members and aid in personalizing risk estimates and
tailoring management.
Although rare, BHD can have significant clinical impli-
cations. There are no well-validated studies of BHD
prevalence [29], but some sources estimate 9 per 1 million
[30]. Of note, up to 5 % of apparent primary spontaneous
pneumothorax have been attributed to underlying BHD
[31]. This highlights the importance of inquiring about
family history, skin abnormalities, and renal disease in in-
dividuals with pneumothorax. It is also important to
recognize that individuals with BHD cystic lung disease
may be underdiagnosed since lung function is generally
well preserved (in contrast to conditions such as LAM).
Conclusion
We describe the largest single family cohort of patients with
BHD syndrome reported to date. All subjects had cystic lung
disease with a significant number experiencing spontaneous
pneumothorax. Cyst size and lower lung zone predominant
disease were associated with pneumothorax occurrence.
Lung function was generally preserved and not affected by a
high cyst burden. Given that BHD-associated pneu-
mothoraces may be severe and recurrent, clinicians may
consider early intervention and thoracic surgery referral.
Abbreviations
BHD: Birt-Hogg-Dubé syndrome; CT: Computed tomography; MRI: Magnetic
resonance imaging; OR: Odds ratio.
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